3-Deazaneplanocin hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 3-Deazaneplanocin hydrochloride
• 英文别名: 5-(4-aminoimidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol;hydrochloride
• 化学式: C12H15ClN4O3
• 分子量: 298.72
• InChiKey: UNSKMHKAFPRFTI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.37
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  117
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• COMBINATION THERAPIES COMPRISING TARGETED THERAPEUTICS
  申请人：Tarveda Therapeutics, Inc.

  公开号：EP3641767A1

  公开（公告）日：2020-04-29
• HSP90-BINDING CONJUGATES AND COMBINATION THERAPIES THEREOF
  申请人：Tarveda Therapeutics, Inc.

  公开号：EP3989980A1

  公开（公告）日：2022-05-04
• COMPOSITE FORMULATION AND USE THEREOF FOR PREPARING DRUGS FOR THE TREATMENT OF TUMOURS
  申请人：TIANJIN MEDICAL UNIVERSITY GENERAL HOSPITAL

  公开号：US20220008375A1

  公开（公告）日：2022-01-13

  The present disclosure relates to the field of biotechnology, and in particular, to a composite formulation and the use thereof for preparing a drug for treating a tumor. The effective components of the composite formulation of the present disclosure at least comprise a compound having a structural formula shown in Formula I and an EZH2 inhibitor. In terms of the clinical application for tumours, the present disclosure finds that a low dose of the compound having the structural formula shown in Formula I can enhance the therapeutic effects of the EZH2 inhibitor DZNEP and, when used in combination, can reduce the dosage of the EZH2 inhibitor DZNEP by ⅘ whilst ensuring pharmaceutical effectiveness, being an effective combination therapeutic solution.
• COMPOSITIONS AND METHODS OF TREATING PIK3CA HELICAL DOMAIN MUTANT CANCERS
  申请人：CASE WESTERN RESERVE UNIVERSITY

  公开号：US20220193056A1

  公开（公告）日：2022-06-23

  A method of treating PIK3CA helical domain mutant cancer in a subject in need thereof includes administering to the subject therapeutically effective amounts of (i) an inhibitor of nuclear translocation of p85β and/or an EZH inhibitor in combination with (ii) a PI3K inhibitor.
• [EN] COMBINATION THERAPIES COMPRISING TARGETED THERAPEUTICS<br/>[FR] POLYTHÉRAPIES COMPRENANT DES AGENTS THÉRAPEUTIQUES CIBLÉS
  申请人：TARVEDA THERAPEUTICS INC

  公开号：WO2018236796A1

  公开（公告）日：2018-12-27

  The invention generally relates to a combination therapy for treating cancer comprising administering at least two distinct therapeutic agents. Components of the combination therapy and methods of using the combination therapy are provided.